FA3
UTSWi003-A
General
Cell Line |
|
| hPSCreg name | UTSWi003-A |
| Cite as: | UTSWi003-A |
| Alternative name(s) |
FA3
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
LUMCi027-A (LUMC0153iPKP03) Donor's gene variants: PKP2 Donor diseases: arrhythmogenic right ventricular dysplasia 9 RCMGi011-A (P10L1) Donor diseases: Mucopolysaccharidosis Type IVB autosomal recessive nonsyndromic deafness 12 RCMGi011-B (P10L2) Donor diseases: Mucopolysaccharidosis Type IVB autosomal recessive nonsyndromic deafness 12 TAUi006-A (UTA.00102.LQT1) Donor's gene variants: KCNQ1 – potassium voltage-gated channel subfamily Q member 1 Donor diseases: Long QT Syndrome 1 TAUi006-B (UTA.00118.LQT1) Donor's gene variants: KCNQ1 – potassium voltage-gated channel subfamily Q member 1 Donor diseases: Long QT Syndrome 1 TAUi007-A (UTA.00208.LQT1) Donor's gene variants: KCNQ1 – potassium voltage-gated channel subfamily Q member 1 Donor diseases: Long QT Syndrome 1 TAUi007-B (UTA.00211.LQT1) Donor's gene variants: KCNQ1 – potassium voltage-gated channel subfamily Q member 1 Donor diseases: Long QT Syndrome 1 |
| Last update | 25th March 2024 |
| User feedback | |
Provider |
|
| Generator | University of Texas Southwestern Medical Center (UTSW) |
| Derivation country | United States |
External Databases |
|
| BioSamples | SAMEA115429408 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
|
| Subclones | |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Is the medical history available upon request? | limited |
| Is clinical information available? | limited |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46XX
Karyotyping method:
G-Banding
|
External Databases (Donor) |
|
| BioSamples | SAMEA115429409 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Provide contact information of the holder of the original Donor Information Sheet: | Dr. David Lynch, CHOP |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Contact information / weblink | Dr. David Lynch |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes |
| Does consent permit access to medical records of the donor? | No |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | CHOP IRB |
| Approval number | 10-007864 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | CHOP IRB |
| Approval number | 10-007864 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell type | |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
Immunostaining, RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
Dispase
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| SSEA-4 |
Yes |
Differentiation Potency
In vitro directed differentiation
Protocol or reference
In vitro directed differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46XX
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.